Insulin Prices, Cancer Treatment Innovation Pushed In State Of The Union As Biden Faces Divided Congress

President Biden’s State of the Union address to Congress on 7 February featured both appeals for bipartisanship and condemnations of his Republican opponents. His discussion of pharmaceuticals offered both extremes: his criticism of drug company profits generating applause on both sides of the aisle, while his declaration that he would veto efforts to weaken Medicare’s new price-setting powers was some of his most fiery rhetoric of the night.

Discussing insulin prices, Biden said, “Big Pharma has been unfairly charging people hundreds of dollars – four to five hundred dollars a month – and making record profits